Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia

BACKGROUND: Imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia leading to significant reductions of BCR-ABL1 transcript levels in peripheral blood. OBJECTIVE: To evaluate the response to imatinib mesylate treatment (400 mg/day) in Brazilian patients in the chronic phase o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Rev Bras Hematol Hemoter
Autori principali: Vieira-Mion, Ana Lucia, Pereira, Noemi Farah, Funke, Vaneuza Araujo Moreira, Pasquini, Ricardo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Sociedade Brasileira de Hematologia e Hemoterapia 2017
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5568590/
https://ncbi.nlm.nih.gov/pubmed/28830599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bjhh.2017.04.007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi